PLRXNMSHealthcare·Biotechnology#374 in industry

Pliant Therapeutics, Inc.

Reports in 10d· 2026-05-07

-4.7% · 90d

$1.21

-0.03 (-2.42%)

After-Hours $1.21(+0.00)

News

(1)

April 2026

Apr 22, 20265 days agoARSHealthcare

PLRX Annual Report Filing Requires Full Content Upload to Proceed

PLRXPLIANT THERAPEUTICS, INC.

I am ready to act as your expert financial analyst and educator! However, the document you provided appears to be a placeholder or a corrupted link. While the system metadata confirms the document is an Annual Report (ARS) for PLIANT THERAPEUTICS, INC., there is no readable text or PDF content attac

Read summaryView on SEC EDGAR

Key Data

Market Cap$74.9M

Open$1.24

Prev Close$1.24

Day Range$1.21 – $1.26

52W Range$1.09 – $1.95

Volume393,656

P/E (TTM)—

EPS$-2.43

Dividend Yield—

Beta1.25

Price Target$2.67(+120.4%)

Next Earnings2026-05-07(10d)

Analyst Ratings

Hold6 analysts

Buy 1Hold 4Sell 1

About

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Healthcare · Biotechnology

49 employees

pliantrx.com